Glorious Drug for the benefits of Multiple Sclerosis!

Thomas · Post by **Thomas** » Tue Mar 06, 2007 11:06 pm

http://www.javno.com/en/world/clanak.php?id=24732

JFH · Post by **JFH** » Wed Mar 07, 2007 1:57 am

Looks decidedly injectable

Post by **Arron** » Wed Mar 07, 2007 2:16 am

I was beyond confused at the title of your post, and then I remembered Borat... ;)

I did a quick look for more information on this therapy, and came up empty, at least in English-language. We'll keep an eye out for it.

Post by **NHE** » Wed Mar 07, 2007 5:09 am

I found this from the pharmaceutical company's site.
http://www.farmacija.co.ba/ridfar.htm

Are Enkorten and FAR404 the same thing?

NHE

dignan · Post by **dignan** » Wed Mar 07, 2007 8:14 am

NHE, I think so. I got to the same place in a similar post in the pipeline section.

connieb · Post by **connieb** » Wed Mar 07, 2007 2:31 pm

I took a very quick look at the information available in Bosnian language-- didn't find too much solid stuff out there-- it looks like Phase II was completed in December. The drug is an immunomodulatory agent of some sort (sorry, don't speak either English or any other language well enough to understand dr-speak). It is administered sub-Q; was tested on 60 RR (I think) patients, half of whom were controls. Again, all I was able to find are references to "many" of them experiencing improvement in MRI and EDSS, as well as in bladder, bowel control, eye function, coordination etc. Looks like it's proceeding to Phase III; some of the testing centers either were or will be (I couldn't understand that part) in Germany.

Post by **Arron** » Wed Mar 07, 2007 2:42 pm

thanks Connie!

Post by **NHE** » Thu Mar 08, 2007 3:10 am

The Farmacija site lists Zahida Ademović as the R&D manager. A search on PubMed yields several papers with Z. Ademović listed as an author. A few of these abstracts discuss cell adhesion via beta-integrins, e.g.,

The recognition of adsorbed and denatured proteins of different topographies by beta2 integrins and effects on leukocyte adhesion and activation. Biomaterials. 2005 Jun;26(16):3039-53.

It may be the case that the drug in trials by Farmacija affect cell adhesion.

NHE

crue · Post by **crue** » Thu Mar 08, 2007 7:14 am

hello and sorry for my bad english,i`m from greece but i know to speak bosnian.
They say that in phase2 trial (30 patients on active drug with average edss 3.5 and 30 patients on placebo with average edss 2.5) the drug compared to placebo reduce the relapses by 60%,edss score reduced by 26% .The drug in bosnia is approved and covered by insurance companys,also they say that foreign patients can buy the drug.

thinkingoutloud86 · Post by **thinkingoutloud86** » Thu Mar 08, 2007 1:25 pm

Hi Crue,

Your English is good. Thank you for the translation. Did you find a reference to the phase II study?

ThinkingOutLoud

sh8un · Post by **sh8un** » Thu Mar 08, 2007 7:04 pm

Crue
Thank you for taking the time to translate. Same to you connib
NN

This Is MS Multiple Sclerosis Knowledge & Support Community

Glorious Drug for the benefits of Multiple Sclerosis!

Glorious Drug for the benefits of Multiple Sclerosis!

Re: Enkorten

Re: FAR404